A NEW SCHEDULE FOR ETOPOSIDE, EPIDOXORUBICIN AND CISPLATIN WITH GRANULOCYTE-COLONY-STIMULATING FACTOR FOR ADVANCED GASTRIC-CANCER - A FEASIBILITY STUDY

Authors
PRONZATO P VIGANI A PENSA F BOTTO F GHIO E NERI E TOGNONI A VAIRA F
Citation
P. Pronzato et al., A NEW SCHEDULE FOR ETOPOSIDE, EPIDOXORUBICIN AND CISPLATIN WITH GRANULOCYTE-COLONY-STIMULATING FACTOR FOR ADVANCED GASTRIC-CANCER - A FEASIBILITY STUDY, Anticancer research, 17(5B), 1997, pp. 3873-3876
Citations number
10
Categorie Soggetti
Oncology
Journal title
Anticancer research → ACNP
ISSN journal
02507005
Volume
17
Issue
5B
Year of publication
1997
Pages
3873 - 3876
Database
ISI
SICI code
0250-7005(1997)17:5B<3873:ANSFEE>2.0.ZU;2-4
Abstract
A new polychemotherapy regimen has been developed for gastric cancer. Etoposide at the dose of 120 mg/m(2) for three days, Epidoxorubicin at the dose of 30 mg/m(2) on day 1 and Cisplatin at the dose of 40 mg/m( 2) on day 2 were administered to 26 advanced gastric patients every tw o weeks with the support of Granulocyte Colony Stimulating Factor from day 8 to day 12 of each cycle. The treatment was feasible with most c ases (21/25) having received at least four cycles with a dose intensit y >85%, without lifethreatening side effects. Toxicity was lower than that observed in the classical combinations of Etoposide-Anthracycline -Cisplatin.